Related Experiment Video
Updated: Apr 27, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Longevity, aging and rapamycin
Abstract:
The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
Insights
Rapamycin, an FDA-approved drug, extends lifespan in mammals by suppressing cancer. It also shows symptomatic benefits for aging traits like cognitive decline, suggesting it primarily targets aging mechanisms through cancer prevention.
Area of Science:
- Gerontology
- Pharmacology
- Molecular Biology
Background:
- Rapamycin is an FDA-approved compound that extends lifespan in mammals.
- A key question is whether rapamycin slows aging or primarily extends longevity by inhibiting cancer, a major cause of death in mice.
Purpose of the Study:
- To review the effects of pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition on aging and longevity in mammals.
- To evaluate current evidence regarding rapamycin's mechanism of lifespan extension.
Main Methods:
- Literature review of studies on rapamycin and mTOR inhibition in mammals.
- Analysis of evidence linking rapamycin's effects to aging processes and cancer suppression.
Main Results:
- Current evidence suggests rapamycin extends lifespan mainly by suppressing cancers.
- Rapamycin also demonstrates symptomatic effects on aging traits, including age-related cognitive impairments.
Conclusions:
- Rapamycin's primary mechanism for lifespan extension in mammals appears to be cancer suppression.
- The drug also offers symptomatic benefits for certain aging-related conditions.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
PI3K/mTOR/AKT Signaling Pathway
Replicative Cell Senescence
Replicative Cell Senescence
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...

